TABLE 1.
Characteristic | Total |
---|---|
Patient characteristics, n = 570 | |
Median age (years [IQR]) | 49 (40–57) |
Median no. of viral load tests (IQR) | 4 (2–6) |
Characteristic, n (%) | |
Age (yrs) | |
<50 | 268 (47) |
≥50 | 302 (53) |
Race/Ethnicity | |
Black, non-Hispanic | 231 (41) |
All other/unknown | 339 (59) |
Sex | |
Male | 444 (78) |
Female | 126 (22) |
Medical insurance | |
Private insurance | 83 (15) |
Nonprivate insurance | 487 (85) |
Viral load test characteristics, n = 2427* | |
PDC category, n (%) | |
<50% | 202 (8) |
50% to <80% | 277 (11) |
80% to <85% | 162 (7) |
85% to <90% | 173 (7) |
≥90% | 1613 (67) |
Viral load test results, n (%) | |
<200 copies/mL | 2180 (90) |
≥200 copies/mL | 247 (10) |
ARV regimen category, n (%)† | |
INSTI-based | 756 (31) |
NNRTI-based | 513 (21) |
PI-Based | 427 (18) |
All other‡ | 731 (30) |
INSTI-NRTI(2)-PI§ | 122 (17) |
INSTI -NNRTI-PI§ | 79 (11) |
INSTI -PI§ | 65 (9) |
INSTI -NNRTI-NRTI(2)§ | 53 (7) |
NRTI(2)-PI(2)§ | 43 (6) |
NNRTI-NRTI(2)-PI§ | 41 (6) |
INSTI -NNRTI-NRTI§ | 40 (6) |
Viral load tests with PDC values and included in the analysis, including the coinciding PDC category, viral load test value, and the coinciding primary ARV regimen.
INSTI-, NNRTI-, and PI-based regimens each included one medication of the main component and 2 nucleoside reverse transcriptase inhibitors (NRTI) as the “backbone” of the therapy.
“All other” category includes all regimens not categorized as an INSTI-, NNRTI-, or PI-based regimen.
The most common regimens within the “all other” category. The parentheses indicate the number of medication types within the regimen.